The global ”women’s health market” size is projected to reach USD 41.05 billion by 2027, exhibiting a CAGR of 3.2% during the forecast period.
The COVID-19 pandemic is likely to reemphasize the importance of women’s health and boost the market, observes Fortune Business Insights™ in its report, titled “Women’s Health Market Size, Share & Industry Analysis, By Application (Contraceptives, Osteoporosis, Menopause, Infertility, and Others) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2020-2027”.The infection caused by the coronavirus, which has affected more men than women across the globe, has brought the issue of health of women in the spotlight.
A UN policy brief released in April 2020 stated that women hold less secure jobs and earn lower wages, which makes them highly vulnerable to the adverse effects of this pandemic.
More importantly, as the pandemic intensifies, women’s health will inevitably suffer.
For example, in March 2020, the UNESCO estimated that the 1.5 billion children worldwide are out of school and this puts female students at a heightened risk of sexual abuse, genital mutilation, and early marriage.
With governments recognizing the significance of maintaining women’s health, the demand for modern, efficient female healthcare products is expected to rise amid this current crisis.Major Women’s Health Market Key players covered in the report include:Agile Therapeutics (New Jersey, USA)LUPIN (Mumbai, India)Merck & Co., Inc. (New Jersey, United States)Amgen Inc. (California, United States)Bayer AG (Leverkusen, Germany)AstraZeneca (Cambridge, UK)Eli Lilly and Company (Indiana, United States)Novartis AG (Basel, Switzerland)Pfizer Inc. (New York, United States)Get Request a Sample Copy of the Women’s Health Report:https://www.fortunebusinessinsights.com/enquiry/sample/women-s-health-market-101847Our research methodology is robust and includes data triangulation based on bottom-up and top-down approaches.